Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Tuesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is anticipated to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.28) per share and revenue of $60.52 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Arcutis Biotherapeutics Stock Down 3.0 %

ARQT stock opened at $13.02 on Friday. Arcutis Biotherapeutics has a 12-month low of $6.99 and a 12-month high of $16.20. The company has a quick ratio of 2.38, a current ratio of 2.46 and a debt-to-equity ratio of 0.67. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -7.27 and a beta of 1.29. The company has a 50 day moving average of $13.66 and a two-hundred day moving average of $11.35.

Insider Activity

In other Arcutis Biotherapeutics news, insider Masaru Matsuda sold 8,338 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.70, for a total value of $105,892.60. Following the sale, the insider now directly owns 178,692 shares in the company, valued at $2,269,388.40. This trade represents a 4.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Todd Franklin Watanabe sold 15,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $15.17, for a total transaction of $227,550.00. Following the completion of the sale, the insider now owns 823,430 shares in the company, valued at $12,491,433.10. This represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,029 shares of company stock worth $756,017. 9.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ARQT shares. Guggenheim reiterated a “buy” rating on shares of Arcutis Biotherapeutics in a research report on Monday, February 10th. Mizuho increased their target price on shares of Arcutis Biotherapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 7th. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 target price on shares of Arcutis Biotherapeutics in a research report on Thursday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of Arcutis Biotherapeutics in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.60.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.